dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.contributor | Ctr Appl Toxicol | |
dc.date.accessioned | 2014-05-20T15:24:22Z | |
dc.date.available | 2014-05-20T15:24:22Z | |
dc.date.created | 2014-05-20T15:24:22Z | |
dc.date.issued | 2004-11-12 | |
dc.identifier | Biochemical and Biophysical Research Communications. San Diego: Academic Press Inc. Elsevier B.V., v. 324, n. 2, p. 661-666, 2004. | |
dc.identifier | 0006-291X | |
dc.identifier | http://hdl.handle.net/11449/34987 | |
dc.identifier | 10.1016/j.bbrc.2004.09.109 | |
dc.identifier | WOS:000224794000028 | |
dc.description.abstract | Roscovitine and flavopiridol have been shown to potently inhibit cyclin-dependent kinase 1 and 2 (CDK1 and 2). The structures of CDK2 complexed with roscovitine and deschoroflavopiridol have been reported, however no crystallographic structure is available for complexes of CDK1 with inhibitors. The present work describes two molecular models for the binary complexes CDK1:roscovitine and CDK1:flavopiridol. These structural models indicate that both inhibitors strongly bind to the ATP-binding pocket of CDKI and structural comparison of the CDK complexes correlates the structures with differences in inhibition of these CDKs by flavopiridol and roscovitine. This article explains the structural basis for the observed differences in activity of these inhibitors. (C) 2004 Elsevier B.V. All rights reserved. | |
dc.language | eng | |
dc.publisher | Elsevier B.V. | |
dc.relation | Biochemical and Biophysical Research Communications | |
dc.relation | 2.559 | |
dc.rights | Acesso restrito | |
dc.source | Web of Science | |
dc.subject | CDK | |
dc.subject | drug design | |
dc.subject | Flavopiridol | |
dc.subject | Roscovitine | |
dc.subject | homology modeling | |
dc.title | Molecular models of cyclin-dependent kinase 1 complexed with inhibitors | |
dc.type | Artículos de revistas | |